Hapvida Participações e Investimentos S.A. (BOVESPA:HAPV3) made a proposal to acquire Notre Dame Intermédica Participações S.A. (BOVESPA:GNDI3) from Alkes II - Fundo de Investimento em Participações Multiestra, managed by BRL Trust Investimentos Ltda. and others for BRL 39.5 billion on January 8, 2021. On February 27, 2021, Hapvida Participações e Investimentos S.A. entered into an associated agreement with Notre Dame Intermédica Participações S.A. As per the agreement, Hapvida Participações e Investimentos S.A. will pay an exchange ration of 5.2490 and BRL 6.45 per share, amounting to BRL 53.5 billion. Hapvida Participações e Investimentos S.A. will issue its shares as consideration. As of January 20, 2022, Hapvida updated exchange ratio to 5.2436 and cash per share to BRL 5.126 due to issueance of dividend of BRL 1 billion by Notre Dame Intermédica. As of February 9, 2022, cash price per share was set to BRL 5.166. Hapvida Participações e Investimentos S.A. shall remain as public listed entity. Post completion, Board of Directors of Hapvida Participações e Investimentos S.A. shall comprise of nine members, of which two members will be appointed by Notre Dame Intermédica Participações S.A., two will be independent members and five members will be appointed by the shareholders of Hapvida Participações e Investimentos S.A., in addition to the intention to maintain the current Chief Executive Officer of Notre Dame Intermédica Participações S.A. in a strategic position in Hapvida Participações e Investimentos S.A. Hapvida's shareholders will own 53.6% of the ne company Protocol and and 46.4% in the combined company. The transaction shall be subject to the approval of the management bodies and shareholding bases of both companies, as well as the applicable regulatory approvals, approval from the Administrative Council for Economic Defense (“CADE”) and the National Supplementary Health Agency (“ANS”). The general meeting will take place on March 1, 2021. The transaction was approved by the board of director of Hapvida Participações e Investimentos S.A. on February 27, 2021. Transaction has been approved at the extraordinary general meetings of Hapvida and GNDI3 held on March 29, 2021. As of December 15, 2021, the Administrative Council for Economic Defense (CADE) approved the transaction. The deal is expected to be completed by start of February 2022. Transaction is expected to close on February 11, 2022.

Banco BTG Pactual S.A. (BOVESPA:BPAC3) and Itaú Unibanco Holding S.A. (BOVESPA:ITUB4) acted as financial advisors to Hapvida Participações e Investimentos S.A. Banco J.P. Morgan S.A. and Citibank, N.A. - Filial Brasileira acted as financial advisors for Notre Dame Intermédica Participações. Carlos Alberto Moreira Lima Jr., Henrique Silva Gordo Lang, Tiago Moreira Vieira Rocha, Cristianne Saccab Zarzur Chaccur, Cauê Rezende Myanaki, Tiago Eler Silva,  Luiz Fernando Lockmann e Souza, Tiago Lopes da Cruz and Carolina Bueno de Oliveira of Pinheiro Neto Advogados and José Luis Camargo, José Senedesi Neto and João Henrique Schpallir Silva of Madrona Advogados acted as a legal advisors to Hapvida Participações e Investimentos S.A. J.P. Morgan Securities LLC, Banco J.P. Morgan S.A. and Citigroup Global Markets Brasil Corretora de Câmbio, Títulos e Valores Mobiliários S.A. acted as a fairness opinion provider and Pedro Whitaker de Souza Dias, Maria Fernanda de Almeida Prado e Silva, Gil Falleiros Mendes, Paulo Camargo Tedesco and Francisco Almeida Prado de Andrade Coutinho of Mattos Filho, Veiga Filho, Marrey Jr. e Quiroga Advogados, Luiz Octavio Lopes, Marcelo Tourinho, Vicente Gioielli and Beatriz Borges of Lefosse Advogados and Carlos José Rolim de Mello, Natália Teixeira Rabaça, Bruno Sartori de Carvalho Barbosa, Fabricio Antonio Cardim de Almeida, Fernando Pinto Xavier Filho, Pedro Henrique Souza de Oliveira and Giovanna Ragazzo of Souza, Mello e Torres Advogados acted as a legal advisors to Notre Dame Intermédica Participações.